FDA Webview
X

Free FDA Notices

Panels to Discuss Bayer’s Trasylol

07/23/2007

Federal Register Notice: FDA’s Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet 9/12, from 8 a.m. to 5 p.m. at the Hilton Washington DC North/Gaithersburg, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD. The committee will discuss clinical data for aprotinin injection (Bayer Pharmaceuticals’ Trasylol), a product indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at increased risk for blood loss and blood transfusion. Contact Mimi Phan, (301) 827- 7001. To view this notice, click here.

LATEST NEWS